John D Isaacs

List of Publications by Year
in descending order

278 papers	18,448 citations	11608 70 h-index	15683 125 g-index
288 all docs	288 docs citations	288 times ranked	21356 citing authors

#	Article	IF	Citations
1	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	13.7	737
2	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. Arthritis and Rheumatism, 2000, 43, 2762-2770.	6.7	611
3	Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood, 2001, 98, 2736-2744.	0.6	551
4	Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 64-71.	6.7	440
5	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 909-920.	0.5	394
6	Cytokines in rheumatoid arthritis â€" shaping the immunological landscape. Nature Reviews Rheumatology, 2016, 12, 63-68.	3.5	385
7	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. Annals of Internal Medicine, 2013, 159, 253.	2.0	381
8	Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. Mechanisms of Ageing and Development, 2012, 133, 456-466.	2.2	347
9	Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells. Journal of Immunology, 2007, 179, 1595-1604.	0.4	319
10	Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet, The, 1992, 340, 748-752.	6.3	309
11	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases, 2014, 73, 349-356.	0.5	308
12	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases, 2010, 69, 1629-1635.	0.5	296
13	Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohnâ€™s disease and ulcerative colitis?. Annals of the Rheumatic Diseases, 2018, 77, 175-187.	0.5	291
14	Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology, 2016, 12, 731-742.	3.5	290
15	Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnology, 2003, 3, 18.	1.7	281
16	Integrated safety in tocilizumab clinical trials. Arthritis Research and Therapy, 2011, 13, R141.	1.6	278
17	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain, 1996, 119, 225-237.	3.7	249
18	Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Annals of the Rheumatic Diseases, 2017, 76, 227-234.	0.5	243

#	Article	IF	Citations
19	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 69-74.	0.5	240
20	Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.. Journal of Clinical Investigation, 1996, 98, 2819-2826.	3.9	227
21	Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet, The, 1993, 341, 1620-1622.	6.3	204
22	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases, 2020, 79, 851-858.	0.5	204
23	Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. Health Technology Assessment, 2017, 21, 1-180.	1.3	195
24	Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. Journal of Clinical Investigation, 2015, 125, 413-424.	3.9	190
25	Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 2042-2050.	0.5	186
26	Biologic therapies in rheumatology: lessons learned, future directions. Nature Reviews Drug Discovery, 2007, 6, 75-92.	21.5	178
27	A randomized, doubleâ€blind, controlled study of ultrasoundâ€guided corticosteroid injection into the joint of patients with inflammatory arthritis. Arthritis and Rheumatism, 2010, 62, 1862-1869.	6.7	175
28	Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 2017, 13, 463-475.	3.5	175
29	The role of biosimilars in the treatment of rheumatic diseases. Annals of the Rheumatic Diseases, 2013, 72, 322-328.	0.5	166
30	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Annals of the Rheumatic Diseases, 2014, 73, 1202-1210.	0.5	166
31	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of the Rheumatic Diseases, 2013, 72, 329-336.	0.5	158
32	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.5	158
33	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood, 2002, 100, 4550-4556.	0.6	152
34	Pathophysiology of rheumatoid arthritis. Current Opinion in Rheumatology, 2011, 23, 233-240.	2.0	151
35	Development of Dendritic Cell-Based Immunotherapy for Autoimmunity. International Reviews of Immunology, 2010, 29, 156-183.	1.5	150
36	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	1.5	146

#	Article	IF	Citations
37	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	6.3	145
38	Genomeâ€wide association study of genetic predictors of antiâ€“tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis and Rheumatism, 2011, 63, 645-653.	6.7	143
39	Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. Gene Therapy, 1999, 6, 939-943.	2.3	137
40	Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?. Clinical and Experimental Immunology, 2013, 172, 148-157.	1.1	134
41	Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 110-116.	0.5	133
42	Therapeutic effect of tolerogenic dendritic cells in established collagenâ€induced arthritis is associated with a reduction in Th17 responses. Arthritis and Rheumatism, 2010, 62, 3656-3665.	6.7	129
43	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. JAMA - Journal of the American Medical Association, 2015, 313, 1645.	3.8	119
44	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1405-1412.	0.5	117
45	Differential regulation of naÃ¯ve and memory CD4+ T cells by alternatively activated dendritic cells. Journal of Leukocyte Biology, 2008, 84, 124-133.	1.5	113
46	Anti-TNF therapy. Best Practice and Research in Clinical Rheumatology, 2011, 25, 549-567.	1.4	113
47	LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. Journal of Leukocyte Biology, 2009, 85, 243-250.	1.5	112
48	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety, 2016, 39, 755-762.	1.4	112
49	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human Molecular Genetics, 2008, 17, 3532-3538.	1.4	111
50	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respiratory Medicine,the, 2020, 8, 822-830.	5.2	110
51	Low-strength T-cell activation promotes Th17 responses. Blood, 2010, 116, 4829-4837.	0.6	108
52	Campath-1H therapy in refractory ocular inflammatory disease. British Journal of Ophthalmology, 2000, 84, 107-109.	2.1	105
53	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	15.2	105
54	Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis. Journal of Autoimmunity, 1998, 11, 255-264.	3.0	103

#	Article	IF	Citations
55	FcÎ³ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis and Rheumatism, 2000, 43, 2328-2334.	6.7	103
56	<scp>CMV</scp> seropositivity and Tâ€cell senescence predict increased cardiovascular mortality in octogenarians: results from the Newcastle 85+ study. Aging Cell, 2016, 15, 389-392.	3.0	103
57	Rheumatoid arthritis risk allele PTPRC is also associated with response to antiâ€“tumor necrosis factor Î± therapy. Arthritis and Rheumatism, 2010, 62, 1849-1861.	6.7	95
58	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology, 2015, 54, 494-499.	0.9	90
59	Clinical Utility of Random Antiâ€“Tumor Necrosis Factor Drugâ€“Level Testing and Measurement of Antidrug Antibodies on the Longâ€Term Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2011-2019.	2.9	90
60	A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clinical and Experimental Immunology, 1996, 106, 427-433.	1.1	89
61	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases, 2010, 69, 1029-1035.	0.5	89
62	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 2022, 81, 1628-1639.	0.5	89
63	The need for personalised medicine for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 4-7.	0.5	88
64	Treg Cells in Rheumatoid Arthritis: An Update. Current Rheumatology Reports, 2013, 15, 352.	2.1	87
65	Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 899-907.	0.5	86
66	Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone. Fertility and Sterility, 1996, 65, 262-266.	0.5	85
67	Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. Genome Biology, 2016, 17, 212.	3.8	85
68	Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Research and Therapy, 2013, 15, R204.	1.6	80
69	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
70	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials, 2019, 20, 429.	0.7	77
71	Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients. JCI Insight, 2019, 4, .	2.3	77
72	Symptom-based stratification of patients with primary SjÃ¶gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	2.2	76

#	Article	IF	Citations
73	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis and Rheumatism, 2001, 44, 1998-2008.	6.7	75
74	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research, 2005, 7, R80.	2.0	75
75	The changing face of rheumatoid arthritis: sustained remission for all?. Nature Reviews Immunology, 2010, 10, 605-611.	10.6	74
76	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFÂB signalling pathways. Annals of the Rheumatic Diseases, 2010, 69, 1315-1320.	0.5	74
77	Maternal Acute Fatty Liver of Pregnancy Associated with Fetal Trifunctional Protein Deficiency: Molecular Characterization of a Novel Maternal Mutant Allele. Pediatric Research, 1996, 40, 393-398.	1.1	73
78	Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: A report of two cases. Obstetrics and Gynecology, 1996, 88, 694-696.	1.2	72
79	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 861-868.	1.5	71
80	A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Annals of the Rheumatic Diseases, 2012, 71, 1374-1381.	0.5	67
81	A Non-Glycosaminoglycan-Binding Variant of CC Chemokine Ligand 7 (Monocyte Chemoattractant) Tj ETQq1 1 0.784314 rgBT /Overl	0.4	66
82	Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Research and Therapy, 2012, 14, R30.	1.6	66
83	CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Journal of Allergy and Clinical Immunology, 2005, 116, 1158-1159.	1.5	65
84	Replication of association of the PTPRC gene with response to antiâ€“tumor necrosis factor therapy in a large UK cohort. Arthritis and Rheumatism, 2012, 64, 665-670.	6.7	65
85	IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 466-473.	0.5	65
86	Neutralizing Tumor Necrosis Factor Activity Leads to Remission in PatientsWith Refractory Noninfectious Posterior Uveitis. JAMA Ophthalmology, 2004, 122, 845.	2.6	64
87	Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7. British Journal of Ophthalmology, 1999, 83, 941-943.	2.1	61
88	Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-Î²1. Clinical and Experimental Immunology, 2016, 187, 113-123.	1.1	60
89	Anti-TNFÎ± Therapy Modulates the Phenotype of Peripheral Blood CD4+T Cells in Patients with Posterior Segment Intraocular Inflammation. , 2004, 45, 170.		59
90	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1353-1360.	2.9	59

#	Article	IF	Citations
91	Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1200-1207.	0.5	57
92	Biosimilars in immuneâ€mediated inflammatory diseases: initial lessons from the first approved biosimilar antiâ€tumour necrosis factor monoclonal antibody. Journal of Internal Medicine, 2016, 279, 41-59.	2.7	56
93	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Annals of the Rheumatic Diseases, 2010, 69, 1054-1057.	0.5	55
94	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2011, 70, 98-103.	0.5	55
95	Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best Practice and Research in Clinical Rheumatology, 2014, 28, 651-659.	1.4	55
96	Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ, 2016, 4, e2300.	0.9	55
97	Regulatory T cells and autoimmunity. Current Opinion in Hematology, 2009, 16, 274-279.	1.2	52
98	Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye, 1995, 9, 564-569.	1.1	51
99	Current concepts in the pathogenesis of early rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 37-48.	1.4	51
100	Basic Mechanisms of JAK Inhibition. Mediterranean Journal of Rheumatology, 2020, 31, 100.	0.3	50
101	Determination of thymic function directly from peripheral blood: A validated modification to an established method. Journal of Immunological Methods, 2008, 339, 185-194.	0.6	49
102	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Annals of the Rheumatic Diseases, 2017, 76, 208-213.	0.5	49
103	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nature Reviews Rheumatology, 2021, 17, 135-144.	3.5	49
104	FcÎ³RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy. PLoS ONE, 2012, 7, e28918.	1.1	49
105	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Research and Therapy, 2006, 8, R109.	1.6	47
106	Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Research and Therapy, 2015, 17, 95.	1.6	46
107	Why is it hard to terminate failing projects in pharmaceutical R&D?. Nature Reviews Drug Discovery, 2015, 14, 663-664.	21.5	46
108	A Transcriptional Signature of Fatigue Derived from Patients with Primary SjÃ¶grenâ€™s Syndrome. PLoS ONE, 2015, 10, e0143970.	1.1	45

#	Article	IF	Citations
109	Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Human Molecular Genetics, 2002, 11, 1449-1453.	1.4	44
110	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis and Rheumatism, 2002, 46, 837-839.	6.7	44
111	Morbidity and mortality in rheumatoid arthritis patients with prolonged therapyâ€induced lymphopenia: Twelveâ€year outcomes. Arthritis and Rheumatism, 2008, 58, 370-375.	6.7	44
112	Tolerising cellular therapies: what is their promise for autoimmune disease?. Annals of the Rheumatic Diseases, 2019, 78, 297-310.	0.5	44
113	Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Annals of the Rheumatic Diseases, 2012, 71, 180-185.	0.5	43
114	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	2.2	43
115	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology, 2020, 59, 1364-1371.	0.9	43
116	Immunogenicity of biologic agents in rheumatology. Nature Reviews Rheumatology, 2021, 17, 81-97.	3.5	43
117	Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.. British Journal of Ophthalmology, 1995, 79, 1054-1055.	2.1	42
118	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 2018, 18, 528-538.	0.9	42
119	The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. Journal of Allergy and Clinical Immunology, 2018, 141, 445-448.e4.	1.5	41
120	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 657-664.	0.9	41
121	Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. Arthritis Research and Therapy, 2006, 8, R93.	1.6	40
122	Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2009, 9, 909-919.	1.4	40
123	Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Research and Therapy, 2014, 16, R158.	1.6	40
124	Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. Clinical and Experimental Immunology, 2000, 122, 109-116.	1.1	39
125	Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Research and Therapy, 2006, 8, R5.	1.6	39
126	A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses. Journal of Immunology, 2014, 193, 1142-1150.	0.4	37

#	Article	IF	Citations
127	CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis. Arthritis and Rheumatology, 2018, 70, 361-370.	2.9	37
128	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.5	37
129	Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Annals of the Rheumatic Diseases, 2005, 64, 1397-1405.	0.5	36
130	Confirmation of association ofFCGR3Bbut notFCGR3Acopy number with susceptibility to autoantibody positive rheumatoid arthritis. Human Mutation, 2012, 33, 741-749.	1.1	36
131	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. Journal of Clinical Investigation, 2001, 107, 519-528.	3.9	36
132	Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Annals of the Rheumatic Diseases, 2008, 67, 750-757.	0.5	35
133	Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-Î± antagonists. Expert Opinion on Biological Therapy, 2009, 9, 1463-1475.	1.4	35
134	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenetics and Genomics, 2009, 19, 319-323.	0.7	35
135	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. BioDrugs, 2020, 34, 27-37.	2.2	35
136	Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertility and Sterility, 1997, 67, 641-643.	0.5	34
137	Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug NaÃ¯ve Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 755.	2.2	34
138	Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. Journal of Autoimmunity, 2019, 105, 102298.	3.0	34
139	Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1927-E1932.	1.8	33
140	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. Arthritis and Rheumatology, 2020, 72, 714-725.	2.9	33
141	Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?. Arthritis Research and Therapy, 2013, 15, R118.	1.6	29
142	Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1873-1879.	0.5	27
143	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 34-40.	0.5	26
144	A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1838-1842.	6.7	25

#	Article	IF	Citations
145	The impact of glycosylation on HLAâ€“DR1â€“restricted T cell recognition of type II collagen in a mouse model. Arthritis and Rheumatism, 2006, 54, 482-491.	6.7	25
146	The biosimilar approval process: how different is it?. Considerations in Medicine, 2017, 1, 3-6.	0.0	25
147	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.5	25
148	T cell immunomodulationâ€"the Holy Grail of therapeutic tolerance. Current Opinion in Pharmacology, 2007, 7, 418-425.	1.7	24
149	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatology, The, 2021, 3, e337-e346.	2.2	24
150	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2023, 82, 65-73.	0.5	24
151	Application of differential display to immunological research. Journal of Immunological Methods, 2001, 250, 29-43.	0.6	23
152	Overexpression of transcripts containing LINE-1 in the synovia of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2003, 62, 663-666.	0.5	23
153	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. Rheumatology, 2016, 55, 1843-1848.	0.9	23
154	Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. Journal of Rheumatology, 2008, 35, 2080-2.	1.0	22
155	Antibody engineering to develop new antirheumatic therapies. Arthritis Research and Therapy, 2009, 11, 225.	1.6	21
156	Immune reconstitution 20Âyears after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Research and Therapy, 2016, 18, 302.	1.6	21
157	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	2.6	21
158	Detection of Mycobacterium tuberculosis Group Organisms in Human and Mouse Joint Tissue by Reverse Transcriptase PCR: Prevalence in Diseased Synovial Tissue Suggests Lack of Specific Association with Rheumatoid Arthritis. Infection and Immunity, 2001, 69, 1821-1831.	1.0	20
159	Thymic function in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 983-990.	0.5	20
160	Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Research and Therapy, 2012, 14, R263.	1.6	20
161	The Darwin Awards: sex differences in idiotic behaviour. BMJ, The, 2014, 349, g7094-g7094.	3.0	20
162	Lost in space: design of experiments and scientific exploration in a Hogarth Universe. Drug Discovery Today, 2015, 20, 1365-1371.	3.2	20

#	Article	IF	Citations
163	R&D productivity rides again?. Pharmaceutical Statistics, 2015, 14, 1-3.	0.7	20
164	Clinical trials of biosimilars should become more similar. Annals of the Rheumatic Diseases, 2017, 76, 4-6.	0.5	20
165	Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci. Journal of Allergy and Clinical Immunology, 2020, 145, 1438-1451.	1.5	20
166	RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial: FigureÂ1. BMJ Open, 2015, 5, e007985.	0.8	19
167	A novel paradigm for dendritic cells as effectors of cartilage destruction. Rheumatology, 2008, 48, 502-507.	0.9	18
168	Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology, 2012, 51, 1397-1406.	0.9	18
169	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Research and Therapy, 2012, 14, R214.	1.6	18
170	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology, 2014, 53, 1344-1346.	0.9	18
171	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet, The, 2015, 385, S48.	6.3	18
172	Targeting of tolerogenic dendritic cells towards heatâ€shock proteins: a novel therapeutic strategy for autoimmune diseases?. Immunology, 2018, 153, 51-59.	2.0	18
173	Interferon-Î±-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. Annals of the Rheumatic Diseases, 2022, 81, 1214-1223.	0.5	18
174	Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nature Reviews Rheumatology, 2011, 7, 507-516.	3.5	17
175	Emerging immunotherapies for rheumatoid arthritis. Human Vaccines and Immunotherapeutics, 2014, 10, 822-837.	1.4	17
176	IL-6 Mediated Transcriptional Programming of NaÃ¯ve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. Frontiers in Immunology, 2019, 10, 1535.	2.2	17
177	Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis. Journal of Translational Medicine, 2019, 17, 375.	1.8	17
178	Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Annals of the Rheumatic Diseases, 2020, 79, 991-993.	0.5	17
179	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. Medicine (United States), 2020, 99, e20458.	0.4	16
180	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight, 2019, 4, .	2.3	16

#	Article	IF	Citations
181	The RA-MAP Consortium: a working model for academiaâ€“industry collaboration. Nature Reviews Rheumatology, 2018, 14, 53-60.	3.5	15
182	Therapeutic tolerance in autoimmune disease. Seminars in Arthritis and Rheumatism, 2018, 48, 558-562.	1.6	15
183	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology, 2016, 55, 2050-2055.	0.9	14
184	Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. Rheumatology, 2019, 58, 1250-1258.	0.9	14
185	Pim Kinases as Therapeutic Targets in Early RheumatoidÂArthritis. Arthritis and Rheumatology, 2021, 73, 1820-1830.	2.9	14
186	Immune reconstitution. Best Practice and Research in Clinical Haematology, 2004, 17, 345-358.	0.7	13
187	â€œLiving a normal lifeâ€¦ a qualitative study of patientsâ€™ views of medication withdrawal in rheumatoid arthritis. BMC Rheumatology, 2019, 3, 2.	0.6	13
188	Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients. Rheumatology, 2019, 58, 1268-1273.	0.9	13
189	T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. Annals of the Rheumatic Diseases, 2007, 66, 599-604.	0.5	12
190	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 299-306.	0.2	12
191	Animal models in infection and inflammation â€“ chance and necessity. European Journal of Immunology, 2009, 39, 1991-1993.	1.6	12
192	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenetics and Genomics, 2010, 20, 338-341.	0.7	12
193	Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery, 2015, 14, 219-221.	21.5	12
194	Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis. Clinical Therapeutics, 2019, 41, 1312-1322.	1.1	12
195	Rheumatoid Arthritis: An Evolutionary Force in Biologics. Current Pharmaceutical Design, 2015, 21, 2170-2178.	0.9	12
196	Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review. RMD Open, 2022, 8, e002058.	1.8	12
197	Immunotherapy of rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1992, 51, 577-579.	0.5	11
198	Prospects for therapeutic tolerance in humans. Current Opinion in Rheumatology, 2014, 26, 219-227.	2.0	11

#	Article	IF	Citations
199	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. Arthritis Research and Therapy, 2021, 23, 80.	1.6	11
200	Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research. Musculoskeletal Care, 2017, 15, 395-399.	0.6	10
201	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology, 2017, 56, kew387.	0.9	10
202	Tolerance-inducing medicines in autoimmunity: rheumatology and beyond. Lancet Rheumatology, The, 2020, 2, e565-e575.	2.2	10
203	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology, 2010, 49, 43-47.	0.9	9
204	Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Annals of the Rheumatic Diseases, 2011, 70, 2056-2058.	0.5	9
205	Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology, 2011, 50, 810-812.	0.9	9
206	Rheumatoid arthritis response to treatment across IgG1 allotype â€“ anti-TNF incompatibility: a case-only study. Arthritis Research and Therapy, 2015, 17, 63.	1.6	9
207	Previously reported PDE3Aâ€“SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics, 2016, 17, 715-720.	0.6	9
208	Latent Class Trajectory Modeling of 2â€Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Diseaseâ€Modifying Antirheumatic Drugs. Arthritis and Rheumatology, 2020, 72, 1632-1642.	2.9	9
209	In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. Expert Review of Clinical Immunology, 2020, 16, 621-630.	1.3	9
210	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. Lancet Rheumatology, The, 2021, 3, e9-e10.	2.2	9
211	Cumulative pregnancy analysis of one-tube versus two-tube tubal anastomosis. Fertility and Sterility, 1997, 68, 217-219.	0.5	8
212	What can rheumatologists learn from translational cancer therapy?. Arthritis Research and Therapy, 2013, 15, 114.	1.6	8
213	Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in <scp>UK</scp> newspapers. Health Expectations, 2017, 20, 309-320.	1.1	8
214	Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists. Pharmaceutical Statistics, 2019, 18, 402-406.	0.7	8
215	Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences, 2021, 66, 2732-2743.	1.1	8
216	Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.. British Journal of Ophthalmology, 1996, 80, 1035-1036.	2.1	7

#	Article	IF	Citations
217	Analysis of the insertion/deletion related polymorphism within T cell antigen receptor Â variable genes in primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2004, 64, 468-470.	0.5	7
218	Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the â€˜age of remissionâ€™?. Expert Opinion on Investigational Drugs, 2009, 18, 1687-1699.	1.9	7
219	Rheumatoid arthritis: from palliation to remission in two decades. Clinical Medicine, 2014, 14, s50-s55.	0.8	7
220	Genotyping in rheumatoid arthritis: a game changer in clinical management?. Expert Review of Clinical Immunology, 2015, 11, 303-305.	1.3	7
221	Use of the dendritic cell marker, B and T lymphocyte attenuator, to identify functionally distinct subsets of human CD1c+ dendritic cells. Lancet, The, 2016, 387, S85.	6.3	7
222	The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis. European Journal of Rheumatology, 2017, 4, 68-69.	1.3	7
223	Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. Rheumatology Advances in Practice, 2019, 3, rkz010.	0.3	7
224	Traceless Cleavage of Proteinâ€“Biotin Conjugates under Biologically Compatible Conditions. ChemBioChem, 2017, 18, 1688-1691.	1.3	7
225	Treating to re-establish tolerance in inflammatory arthritis â€“ lessons from other diseases. Best Practice and Research in Clinical Rheumatology, 2010, 24, 497-511.	1.4	6
226	Novel immunotherapies for rheumatoid arthritis. Clinical Medicine, 2013, 13, 391-394.	0.8	6
227	Testing the role of vitamin D in response to antitumour necrosis factor Î± therapy in a UK cohort: a Mendelian randomisation approach. Annals of the Rheumatic Diseases, 2014, 73, 938-940.	0.5	6
228	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Research and Therapy, 2015, 17, 359.	1.6	6
229	Letâ€™s not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!. Annals of the Rheumatic Diseases, 2017, 76, e12-e12.	0.5	6
230	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2091532.	1.2	6
231	Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110439.	1.2	6
232	Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting?. Eye, 2001, 15, 492-496.	1.1	5
233	Teaching examples for the design of experiments: geographical sensitivity and the selfâ€fulfilling prophecy. Pharmaceutical Statistics, 2016, 15, 90-92.	0.7	5
234	Unique TCR Î²-subunit variable gene haplotypes in Africans. Immunogenetics, 2002, 53, 884-893.	1.2	4

#	Article	IF	Citations
235	Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12Âmonths. Clinical Rheumatology, 2011, 30, 1137-1138.	1.0	4
236	Retrospective analysis of the role of serum vitamin D in early rheumatic disease. Rheumatology, 2015, 54, 374-375.	0.9	4
237	10 years of therapeutic advances in the rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 628-630.	3.5	4
238	SchrÃ¶dingerâ€™s pipeline and the outsourcing of pharmaceutical innovation. Drug Discovery Today, 2020, 25, 480-484.	3.2	4
239	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. BMC Rheumatology, 2021, 5, 22.	0.6	4
240	Tolerogenic Dendritic Cells in Clinical Practice. Open Arthritis Journal, 2010, 3, 8-12.	0.0	4
241	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. Scientific Data, 2022, 9, 196.	2.4	4
242	Long-term immunologic effects of alemtuzumab: immune reconstitution and immune function after alemtuzumab therapy for autoimmune disease. Transplantation Reviews, 2003, 17, S12-S15.	1.2	3
243	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics Journal, 2014, 14, 171-175.	0.9	3
244	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. Rheumatology, 2017, 56, kew416.	0.9	3
245	Bclâ€3 in CD4+ T Cellâ€“Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al. Arthritis and Rheumatology, 2016, 68, 770-771.	2.9	3
246	Pharmacogenetics of TNF inhibitorÂresponse in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics, 2020, 21, 1151-1156.	0.6	3
247	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. Rheumatology, 2022, 61, 4935-4944.	0.9	3
248	Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic. Pharmaceutical Statistics, 2019, 18, 632-635.	0.7	2
249	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach. Clinical Proteomics, 2021, 18, 20.	1.1	2
250	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. , 2008, , 169-185.		2
251	Therapeutic immunosuppression of T cells. Current Opinion in Biotechnology, 1992, 3, 668-674.	3.3	1
252	No strong association between alleles of tumour necrosis factor alpha and interleukin-1 receptor antagonist and corneal melting associated with systemic vasculitis. British Journal of Ophthalmology, 2000, 84, 395-398.	2.1	1

#	Article	IF	Citations
253	Investigation of interleukin-6-driven STAT3 signalling in circulating lymphocytes of patients with early rheumatoid arthritis as a route to biomarker discovery. Lancet, The, 2014, 383, S84.	6.3	1
254	Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	1
255	I081â€ƒApproach to therapy in refractory rheumatoid arthritis. Rheumatology, 2019, 58, .	0.9	1
256	Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?. Lancet Rheumatology, The, 2021, 3, e371-e382.	2.2	1
257	P187â€ƒPre-defined Gene Co-expression Modules in Rheumatoid Arthritis Transition towards Molecular Health following Tumour Necrosis Factor Inhibitor Therapy. Rheumatology, 2022, 61, .	0.9	1
258	Fc? receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al. Arthritis and Rheumatism, 2004, 50, 1352-1353.	6.7	0
259	Thymic function and immune senescence in juvenile idiopathic arthritis: Comment on the article by Prelog et al. Arthritis and Rheumatism, 2009, 60, 310-311.	6.7	0
260	Translating cutting edge science into novel and effective therapies. Current Opinion in Pharmacology, 2010, 10, 300-301.	1.7	0
261	Rheumatology Conference Highlights. International Journal of Clinical Rheumatology, 2012, 7, 33-35.	0.3	0
262	Effect of inadequate adherence on clinical outcomes: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Lancet, The, 2014, 383, S26.	6.3	0
263	054.â€ƒThe Importance of IL-6-STAT3 Mediated Activation of Circulating CD4⁺ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. Rheumatology, 2015, , .	0.9	0
264	O49.â€ƒPersonalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritisâ€”Multi-Centre Prospective Cohort Studies. Rheumatology, 2015, , .	0.9	0
265	O50â€ƒHigh Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. Rheumatology, 0, , .	0.9	0
266	02.29â€¦Exploring pim1 as a measurable therapeutic target in early rheumatoid arthritis. , 2017, , .		0
267	Considering biosimilar policy. Considerations in Medicine, 2017, 1, 19-24.	0.0	0
268	271â€ƒInterleukin-1Î² expressing inflammatory macrophages in temporal arteries affected by giant cell arteritis. Rheumatology, 2019, 58, .	0.9	0
269	023â€ƒGeneration and validation of an in vitro model of Langhans-type multinucleated giant cells to investigate giant cell arteritis. Rheumatology, 2019, 58, .	0.9	0
270	I091â€ƒDevelopment of novel therapeutics for inflammatory arthritis. Rheumatology, 2019, 58, .	0.9	0

#	Article	IF	Citations
271	SAT0003â€…PIM1 REGULATES CD4+ T CELL EFFECTOR FUNCTION IN EARLY RHEUMATOID ARTHRITIS AND HAS POTENTIAL FOR USE AS A NOVEL, MEASURABLE THERAPEUTIC TARGET. , 2019, , .		0
272	FRI0009â€…MOLECULAR PROFILING OF CIRCULATING B-LYMPHOCYTES REVEALS THE SUPERIOR PERFORMANCE OF METHYLOME OVER TRANSCRIPTOME DATA FOR DISCRIMINATING RHEUMATOID ARTHRITIS PATIENTS IN AN EARLY ARTHRITIS CLINIC: IMPLICATIONS FOR TRANSLATING â€œBIG DATAâ€•INTO CLINICALLY USEFUL TOOLS. , 2019, , .		0
273	O11â€ƒLymphocyte DNA methylation mediates genetic risk at RA risk loci that are shared with other immune mediated diseases. Rheumatology, 2020, 59, .	0.9	0
274	Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2021, 326, 872.	3.8	0
275	Differential Display Reverse Transcription-Polymerase Chain Reaction to Identify Novel Biomolecules in Arthritis Research. Methods in Molecular Medicine, 2007, 136, 329-347.	0.8	0
276	P186â€ƒThe association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review. Rheumatology, 2022, 61, .	0.9	0
277	OA15â€ƒDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
278	OA16â€ƒTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. Rheumatology, 2022, 61, .	0.9	0